Adding tagitanlimab to treatment with gemcitabine and cisplatin improved PFS in patients with recurrent or metastatic nasopharyngeal cancer.

Adding nivolumab to adjuvant CRT improved DFS in patients with locally advanced head and neck squamous cell carcinoma at high risk of relapse.